genetic analysis
Teva buys majority stake in genomic analysis firm
August 4, 2015Manufacturing and Production, Research and Development, Sales and Marketing CNS, Immuneering, Teva, central nervous system, genetic analysis
Teva has agreed to by a 51% equity share of genomic-analysis company Immuneering to advance treatments for diseases of the …
Latest content
The evidence bar impacting UK medical cannabis access
November 6, 2026
Addressing the rheumatic disease diagnostic gap in primary care
November 5, 2026
